179 related articles for article (PubMed ID: 24722287)
1. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Tsai AC; Wang CY; Liou JP; Pai HC; Hsiao CJ; Chang JY; Wang JC; Teng CM; Pan SL
Cell Death Dis; 2014 Apr; 5(4):e1162. PubMed ID: 24722287
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Tsai AC; Pai HC; Wang CY; Liou JP; Teng CM; Wang JC; Pan SL
Br J Pharmacol; 2014 Jan; 171(1):122-33. PubMed ID: 24116948
[TBL] [Abstract][Full Text] [Related]
3. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
5. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
6. Investigation of anti-tumor mechanisms of K2154: characterization of tubulin isotypes, mitotic arrest and apoptotic machinery.
Lu PH; Kung FL; Kuo SC; Chueh SC; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):223-33. PubMed ID: 17102938
[TBL] [Abstract][Full Text] [Related]
7. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
8. Magnolol Inhibits the Growth of Non-Small Cell Lung Cancer via Inhibiting Microtubule Polymerization.
Shen J; Ma H; Zhang T; Liu H; Yu L; Li G; Li H; Hu M
Cell Physiol Biochem; 2017; 42(5):1789-1801. PubMed ID: 28746938
[TBL] [Abstract][Full Text] [Related]
9. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
10. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
Whang YM; Park KH; Jung HY; Jo UH; Kim YH
Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
[TBL] [Abstract][Full Text] [Related]
11. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
12. 2-APCAs, the Novel Microtubule Targeting Agents Active Against Distinct Cancer Cell Lines.
Boichuk S; Galembikova A; Bikinieva F; Dunaev P; Aukhadieva A; Syuzov K; Zykova S; Igidov N; Ksenofontov A; Bocharov P
Molecules; 2021 Jan; 26(3):. PubMed ID: 33503939
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
14. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
15. Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Meng X; Laidler LL; Kosmacek EA; Yang S; Xiong Z; Zhu D; Wang X; Dai D; Zhang Y; Wang X; Brachova P; Albitar L; Liu D; Ianzini F; Mackey MA; Leslie KK
Gynecol Oncol; 2013 Mar; 128(3):461-9. PubMed ID: 23146687
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway.
Ho CH; Hsu JL; Liu SP; Hsu LC; Chang WL; Chao CC; Guh JH
Prostate; 2015 Sep; 75(13):1454-66. PubMed ID: 26180030
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ
Curr Pharm Des; 2013; 19(5):927-39. PubMed ID: 22973961
[TBL] [Abstract][Full Text] [Related]
18. An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.
Rai A; Surolia A; Panda D
PLoS One; 2012; 7(8):e44311. PubMed ID: 22952952
[TBL] [Abstract][Full Text] [Related]
19. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
20. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
